Abstract:Objective To investigate the clinical characteristics,associated risk factors and therapeutic effectiveness of chronic graft-versus-host disease(cGVHD)after allogeneic hematopoietic stem cell transplantation(allo-HSCT).Methods The clinical data of cGVHD were retrospectively analyzed from 69 patients who underwent alIo-HSCT.All patients were divided into three groups according to the relation between donor and recipient and HLA matching:22 patients of sibling- matched bone marrow transplantation in group A;37 patients of sibling-matched peripheral blood stem cell transplantation in group B;10 patients of matched unrelated donor HSCT or sibling-mismatched HSCT in group C.All of them were subjected to chemotherapy for preconditioning before transplanta- tion,and short-term methoterexate(MTX)combined with cyclosporine(CsA)for GVHD prophylaxis after transplantation.Patients with limited cGVHD were usually treated with immunosuppressive agent(CsA or glucocorticoid)alone,and those with advanced condition were administrated with stan- dard regimen(CsA combined with glucocorticoid);while those with extensive cGVHD were treated with standard regimen(first line therapy).Those who were not responsive to first line therapy and had a progressive disease condition,or those who were refractory to the first line therapy and relapsed when drug withdrawal were treated with tacrolimus,mycophenolate and azathioprine(second line therapy).Results During a median follow-up period of 43 months(6-120 months),39 patients deve- loped cGVHD after transplantation.Limited cGVHD developed in 13 of 39 patients(33.3%),while extensive cGVHD developed in 26 of 39 patients(66.7%).Seven died of cGVHD or related compli- cations,cGVHD incidence in group B was much higher than in group A(P0.05),while incidence of extensive cGVHD in groups B and C were much higher than in group A(P0,05).Peripheral blood stem cell transplant and development of gradeⅡ-Ⅳacute GVHD were the independent risk factors of cGVHD.It was also proven that patients with limited eGVHD who treated with first line therapy had a better therapeutic effect than those with extensive cGVHD(P0.05);therapeutic effectiveness of first line therapy for cGVHD in standard risk group was much better than that in high risk group(P0.05).Conclusion cGVHD is the common complication and reasons of causing death in later period after allo-HSCT.Clinically extensive cGVHD usually develops in patients undergoing allo-PBSCT, HLA mismatched HSCT and MUD-HSCT,and has a worse clinical therapeutic effect.

Expression of CD158 in Refractory Chronic Graft-Versus-host Diseases Treated with Tacrolimus, Mycophenolate Mofetil Combined with Methylprednisone

A High Frequency of CD8+CD28- T-suppressor Cells Contributes to Maintaining Stable Graft Function and Reducing Immunosuppressant Dosage after Liver Transplantation

Efficacy of Cyclosporine A Combined with Mycophenolate Mofetil on Graft-Versus-host Disease after Allogeneic Hematopoietic Stem Cell Transplantation

[Mycophenolate Mofetil in Treatment of Graft-Versus-host Disease after Allogeneic Hematopoietic Cell Transplantation: Analysis of 44 Cases].

Combination of C-X-C motif chemokine 9 and C-X-C motif chemokine 10 antibodies with FTY720 prolongs the survival of cardiac retransplantation allografts in a mouse model

Therapeutic effect of Rituximab on refractory extensive chronic graft-versus-host disease

Study on the Molecular Mechanism of Treatment with Mycophenolate Mofetil on GVHD

Prophylaxis and treatment of chronic graft versus host disease]

[Combination of Mycophenolate Mofetil with Cyclosporine A and Methotrexate for the Prophylaxes of Acute Graft Versus Host Disease in Allogeneic Peripheral Stem Cell Transplantation].

Expression of Killer Cell Inhibitor Receptors on Immunocompetent Cells with Relation to Graft-Versus-host Disease after Hematopoietic Stem Cell Transplantation.

Analysis of T Lymphocyte Subgroups and CD28-family Co-Stimulators in Allo-Liver Recipients Receiving Tacrolimus Treatment

A combined strategy of surface markers for sorting immune cell subsets in patients with chronic graft-versus-host disease

[Prophylactic Effect of CsA, MTX, MMF Combined with ATG on GVHD in Patients Underwent Unrelated Peripheral Blood Hematopoietic Stem Cell Transplantation].

The Expression of Natural Killer Cells Inhibitory Receptors on Natural Killer Cells and T Lymphocytes and the Relationship with Acute Graft-Versus-host Disease

Therapeutic efficacy of rituximab combined with cyclosporin A on B-cell dysregulation in chronic graft-versus-host disease

Treatment of Graft Vs Host Disease by Blockage of T Cells Growth Factor Receptor Pathway

Expression of T-cell receptor Vβ gene in the patients with graft vs host disease

Comparison of Tacrolimus and Cyclosporine Combined with Methotrexate for Graft Versus Host Disease Prophylaxis after Allogeneic Hematopoietic Cell Transplantation.

Significance of the expressions of CD40 and CD40 ligand to graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

Chronic graft-versus-host disease: Pathogenesis and clinical management

Clinical Study of Chronic Graft-Versus-host Disease after Allogeneic Hematopoietic Stem Cell Transplantation